In this article, we will discuss Brigatinib (Dosage Overview). So, let’s get started.
Brigatinib is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
The recommended dosing regimen for Brigatinib is:
• 90 mg orally once daily for the first 7 days;
• if 90 mg is tolerated during the first 7 days, increase the dose to 180 mg orally once daily.
Administer Brigatinib until disease progression or unacceptable toxicity.
If Brigatinib is interrupted for 14 days or longer for reasons other than adverse reactions, resume treatment at 90 mg once daily for 7 days before increasing to the previously tolerated dose.
Brigatinib may be taken with or without food.
If a dose of Brigatinib is missed or vomiting occurs after taking a dose, do not administer an additional dose and take the next dose
of Brigatinib at the scheduled time.